Bio-Rad to take $80 million to $90 million in restructuring charges; Q2 sales flat
On July 31, 2026, Bio-Rad started a restructuring plan that removes certain positions, consolidates functions and closes various facilities, with pre-tax charges estimated at $80 million to $90 million. The same day, it reported second-quarter 2026 net sales of $651.0 million, essentially flat year over year, and reaffirmed its full-year 2026 outlook. GAAP net income rose to $371.4 million mainly because of a gain on its Sartorius AG investment, while non-GAAP net income was $70.2 million, slightly below the prior year.
Key points
- Restructuring plan initiated July 31, 2026; estimated pre-tax charges of $80 million to $90 million, mostly termination benefits; expected to be substantially complete by the end of fiscal 2027.
- Q2 2026 net sales $651.0 million vs. $651.6 million in Q2 2025; currency-neutral sales down 1.9 percent.
- GAAP diluted EPS $13.85 vs. $11.67, driven by a change in the fair market value of the Sartorius AG investment; non-GAAP diluted EPS $2.62 vs. $2.61.
- Full-year 2026 outlook reaffirmed: non-GAAP currency-neutral revenue decline of about 3.0 percent to growth of about 0.5 percent; non-GAAP operating margin of about 10.0 to 12.0 percent.
The filing
Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.